New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - emtricitabine 200mg;  ; tenofovir disoproxil maleate 300mg equivalent to tenofovir disoproxil 245 mg; emtricitabine 200mg; tenofovir disoproxil maleate 300mg equivalent to tenofovir disoproxil 245 mg - film coated tablet - 200 mg/300 mg - active: emtricitabine 200mg   tenofovir disoproxil maleate 300mg equivalent to tenofovir disoproxil 245 mg excipient: colloidal silicon dioxide hyprolose iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose opadry green 31k510010 active: emtricitabine 200mg tenofovir disoproxil maleate 300mg equivalent to tenofovir disoproxil 245 mg excipient: colloidal silicon dioxide hyprolose iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose opadry green 32k510087 - treatment of hiv-1 infection tenofovir disoproxil emtricitabine viatris is indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - fenofibrate, quantity: 48 mg - tablet - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; lactose monohydrate; sucrose; hypromellose; docusate sodium; magnesium stearate; colloidal anhydrous silica; crospovidone; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; xanthan gum; polyvinyl alcohol; quinoline yellow aluminium lake; lecithin; indigo carmine aluminium lake - fenofibrate viatris is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia; - types ii, iii, iv and v dyslipidaemia; - dyslipidaemia associated with type 2 diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - fenofibrate, quantity: 145 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium lauryl sulfate; crospovidone; hypromellose; magnesium stearate; lactose monohydrate; docusate sodium; microcrystalline cellulose; sucrose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - fenofibrate viatris is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia; - types ii, iii, iv and v dyslipidaemia; - dyslipidaemia associated with type 2 diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - oxycodone hydrochloride, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose; microcrystalline cellulose; stearic acid - oxycodone viatris is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - atazanavir sulfate 170.85mg equivalent to atazanavir 150mg; atazanavir sulfate 170.85mg equivalent to atazanavir 150mg - capsule - 150 mg - active: atazanavir sulfate 170.85mg equivalent to atazanavir 150mg excipient: crospovidone gelatin   iron oxide red lactose monohydrate magnesium stearate patent blue v   purified water   tekprint black sw-9008 titanium dioxide   active: atazanavir sulfate 170.85mg equivalent to atazanavir 150mg excipient: brilliant blue fcf   crospovidone erythrosine gelatin iron oxide yellow lactose monohydrate magnesium stearate purified water   titanium dioxide   - atazanavir viatris is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents, in adult patients and in paediatric patients 6 to 18 years of age. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - atazanavir sulfate 227.8mg equivalent to atazanavir 200mg; atazanavir sulfate 227.8mg equivalent to atazanavir 200mg - capsule - 200 mg - active: atazanavir sulfate 227.8mg equivalent to atazanavir 200mg excipient: brilliant blue fcf   crospovidone erythrosine gelatin   lactose monohydrate magnesium stearate purified water   titanium dioxide   active: atazanavir sulfate 227.8mg equivalent to atazanavir 200mg excipient: crospovidone gelatin   indigo carmine iron oxide yellow lactose monohydrate magnesium stearate patent blue v purified water   tekprint black sw-9008 titanium dioxide   - atazanavir viatris is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents, in adult patients and in paediatric patients 6 to 18 years of age. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - atazanavir sulfate 341.7mg equivalent to atazanavir 300mg; atazanavir sulfate 341.7mg equivalent to atazanavir 300mg - capsule - 300 mg - active: atazanavir sulfate 341.7mg equivalent to atazanavir 300mg excipient: brilliant blue fcf crospovidone erythrosine gelatin   iron oxide red iron oxide yellow lactose monohydrate magnesium stearate purified water   titanium dioxide   active: atazanavir sulfate 341.7mg equivalent to atazanavir 300mg excipient: crospovidone gelatin   iron oxide red   iron oxide yellow lactose monohydrate magnesium stearate patent blue v purified water   tekprint black sw-9008 titanium dioxide   - atazanavir viatris is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents, in adult patients and in paediatric patients 6 to 18 years of age. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - capecitabine 150mg;  ;   - film coated tablet - 150 mg - active: capecitabine 150mg     excipient: croscarmellose sodium hypromellose   iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose purified talc purified water titanium dioxide - capecitabine viatris tablets in combination with docetaxel is indicated for the treatment of patients with locally-advanced or metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. capecitabine viatris tablets as monotherapy is indicated for the treatment of patients with locally-advanced or metastatic breast cancer after failure of both a taxane-containing and anthracycline-containing chemotherapy or in whom taxane-containing and anthracycline-containing therapy are not indicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - capecitabine 500mg;  ;   - film coated tablet - 500 mg - active: capecitabine 500mg     excipient: croscarmellose sodium hypromellose   iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose purified talc purified water titanium dioxide - capecitabine viatris tablets in combination with docetaxel is indicated for the treatment of patients with locally-advanced or metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. capecitabine viatris tablets as monotherapy is indicated for the treatment of patients with locally-advanced or metastatic breast cancer after failure of both a taxane-containing and anthracycline-containing chemotherapy or in whom taxane-containing and anthracycline-containing therapy are not indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

helix pharmaceuticals pty ltd - meloxicam, quantity: 7.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; povidone; magnesium stearate; sodium citrate dihydrate; colloidal anhydrous silica; crospovidone; microcrystalline cellulose - meloxicam is indicated for symptomatic treatment of osteoarthritis and rheumatoid arthritis.